🇺🇸 FDA
Patent

US 7033771

Use of insulin response modulators in the treatment of diabetes and insulin resistance

expired A61KA61K2039/505A61K38/1709

Quick answer

US patent 7033771 (Use of insulin response modulators in the treatment of diabetes and insulin resistance) held by Takeda Pharmaceutical Company Limited expires Mon Apr 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Apr 25 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K38/1709